WallStSmart

Cencora Inc. (COR)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 125733% more annual revenue ($325.78B vs $258.90M). COR leads profitability with a 0.5% profit margin vs -15.5%. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.0Value: 7.3Quality: 5.0

ZEPP

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-43.9%)

Margin of Safety

-43.9%

Fair Value

$254.20

Current Price

$325.08

$70.88 premium

UndervaluedFair: $254.20Overvalued

Intrinsic value data unavailable for ZEPP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR3 strengths · Avg: 9.0/10
Return on EquityProfitability
133.5%10/10

Every $100 of equity generates 134 in profit

Market CapQuality
$63.59B9/10

Large-cap with strong market position

PEG RatioValuation
0.788/10

Growing faster than its price suggests

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

COR4 concerns · Avg: 3.0/10
P/E RatioValuation
39.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Price/BookValuation
33.1x2/10

Trading at 33.1x book value

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$216.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : COR

The primary concerns for COR are P/E Ratio, Profit Margin, Operating Margin. Thin 0.5% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

COR profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (62/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?